Get the Stockscreener App
14.91
6.12%
0.86
Pre-market:
14.57
-0.34
-2.28%
Uniqure N V stock is traded at $14.91, with a volume of 896.80K.
It is up +6.12% in the last 24 hours and down -12.19% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$14.05
Open:
$13.97
24h Volume:
896.80K
Relative Volume:
0.43
Market Cap:
$726.76M
Revenue:
$15.84M
Net Income/Loss:
$-308.48M
P/E Ratio:
-2.3009
EPS:
-6.48
Net Cash Flow:
$-153.08M
1W Performance:
+12.70%
1M Performance:
-12.19%
6M Performance:
+92.64%
1Y Performance:
+168.65%
1-Day Range:
$13.70
$15.18
1-Week Range:
$13.33
$15.18
52-Week Range:
$3.73
$19.18
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
14.91 | 726.76M | 15.84M | -308.48M | -153.08M | -6.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
uniQure (NASDAQ:QURE) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat
(QURE) Technical Pivots with Risk Controls - Stock Traders Daily
Hemophilia B Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Pfizer, Spark Therapeutics, Sanofi, Alnylam Pharma, CSL Behring, uniQure, Novo Nordisk - The Globe and Mail
Sanders Morris Harris LLC Increases Stake in uniQure (NASDAQ:QURE) - MarketBeat
Short Interest in uniQure (NASDAQ:QURE) Declines By 21.2% - MarketBeat
Here’s Why uniQure N.V. (QURE) Is Skyrocketing - MSN
Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025? - Insider Monkey
(QURE) Trading Signals - Stock Traders Daily
uniQure sets $17 share price for $75 million offering By Investing.com - Investing.com Nigeria
uniQure (NASDAQ:QURE) Receives $33.88 Consensus Target Price from Brokerages - MarketBeat
uniQure (NASDAQ:QURE) Sees Strong Trading VolumeStill a Buy? - MarketBeat
uniQure sets $17 share price for $75 million offering - Investing.com India
uniQure Announces Pricing of its Public Offering - The Manila Times
uniQure Prices $75 Million Public Offering at $17.00 Per Share to Boost Growth Capital - StockTitan
uniQure Announces Proposed Public Offering - The Manila Times
uniQure Announces Public Offering of Ordinary Shares and Pre-Funded Warrants - StockTitan
UniQure stock soars to 52-week high, hits $18.5 amid robust gains - Investing.com Canada
uniQure (NASDAQ:QURE) Sets New 1-Year HighHere's What Happened - MarketBeat
uniQure (NASDAQ:QURE) Shares Down 3.5%What's Next? - MarketBeat
uniQure (NASDAQ:QURE) Shares Gap DownHere's What Happened - MarketBeat
Uniqure stock soars to 52-week high, reaches $18.14 By Investing.com - Investing.com Canada
Uniqure stock soars to 52-week high, reaches $18.14 - Investing.com India
How the (QURE) price action is used to our Advantage - Stock Traders Daily
uniQure (NASDAQ:QURE) Shares Gap UpStill a Buy? - MarketBeat
UniQure stock soars to 52-week high, hits $17.75 amid robust gains By Investing.com - Investing.com South Africa
UniQure stock soars to 52-week high, hits $17.75 amid robust gains - Investing.com Nigeria
Franklin Resources Inc. Makes New $7.36 Million Investment in uniQure (NASDAQ:QURE) - MarketBeat
uniQure (NASDAQ:QURE) Trading 5.8% Higher Following Analyst Upgrade - MarketBeat
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug - MSN
uniQure (NASDAQ:QURE) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
CSL and uniQure Win 2023 Prix Galien USA Award - GuruFocus.com
57,333 Shares in uniQure (NASDAQ:QURE) Purchased by Y Intercept Hong Kong Ltd - MarketBeat
Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024 - CGTLive™
uniQure price target raised to $32 from $12 at Stifel - Yahoo Finance
uniQure (NASDAQ:QURE) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
uniQure (NASDAQ:QURE) Price Target Raised to $32.00 at Stifel Nicolaus - MarketBeat
uniQure (NASDAQ:QURE) Shares Acquired by Fmr LLC - MarketBeat
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025? - Yahoo Finance
uniQure (NASDAQ:QURE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):